Clinical Trials on Heterotopic Gastric Mucosa of the Proximal Esophagus in New Zealand

Total 40 results

National Cancer Institute (NCI)

Terminated

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma... and other conditions

United States
Keythera Pharmaceuticals (Australia) Pty Ltd

Recruiting

A Study of KF-0210 in Advanced Solid Tumors Patients

Gastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the Esophagus

Australia
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage III Mucosal Melanoma of the Head and Neck | Stage IVA Mucosal Melanoma of the Head and Neck | Stage IVB Mucosal Melanoma of the Head and Neck | Stage IVC Mucosal Melanoma...

United States
National Cancer Institute (NCI)

Completed

Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Stage III Esophageal Cancer

United States
National Cancer Institute (NCI)

Completed

Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
Taiho Oncology, Inc.

Terminated

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST)

Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction

Belgium, Spain, United States, Italy, Estonia, Russian Federation, Bulgaria, Hungary, Croatia, Israel, Mexico, Poland, Portugal, Romania, South Africa, Ukraine, United Kingdom, Brazil, Germany, Argentina
Bristol-Myers Squibb

Completed

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

France, Poland, Russian Federation, Taiwan, United States, Hong Kong, Spain, Germany, Italy, Japan, Korea, Republic of, Singapore
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
National Cancer Institute (NCI)

Completed

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Recurrent Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Stage IV Ovarian Epithelial Cancer | Stage IIIB Breast Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell... and other conditions

United States
Albert Einstein College of Medicine

Completed

Real-time Activity Monitoring to Prevent Admissions During RadioTherapy (RAMPART)

Cancer of Stomach | Cancer of Lung | Cancer of Esophagus | Cancer of the Head and Neck

United States
National Cancer Institute (NCI)

Recruiting

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Mucosal Melanoma | Anal Melanoma | Bladder Melanoma | Cervical Melanoma | Esophageal Melanoma | Gallbladder Melanoma | Mucosal Melanoma of the Head and Neck | Mucosal Melanoma of the Urinary System | Oral Cavity Mucosal Melanoma | Penile Mucosal Melanoma | Rectal Melanoma | Recurrent Mucosal Melanoma | Sinonasal... and other conditions

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Gastric Cancer | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract

Melanoma | Sarcoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Bile Duct Neoplasms | Liver Cancer

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Recurrent Gastric Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Diffuse Gastric Adenocarcinoma | Gastric Intestinal Type Adenocarcinoma | Gastric Mixed Adenocarcinoma

United States, Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Adenocarcinoma | Recurrent Gastric Carcinoma | Esophageal Undifferentiated Carcinoma | Gastric Squamous Cell Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IV Esophageal Adenocarcinoma | Stage... and other conditions

United States
Gulam Manji
Merck Sharp & Dohme LLC

Completed

Perioperative Chemo and Pembrolizumab in Gastric Cancer

Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Bristol-Myers Squibb

Completed

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Gastric Cancer | Esophagogastric Junction | Cancer of the Stomach

United States, Germany, Italy, Argentina, Australia, Belgium, France, Poland, Puerto Rico, Spain, Czechia, Austria, Canada, United Kingdom, Chile, Norway, Singapore
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

United States, Spain, Italy, Australia, Russian Federation, Taiwan, Korea, Republic of, Thailand, Canada, Turkey, Germany, Romania, United Kingdom, Hungary, Brazil, France, Japan
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Terminated

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

HIV Infection | Unspecified Adult Solid Tumor, Protocol Specific | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIC Breast Cancer | Adenocarcinoma of the Gastroesophageal Junction | Recurrent Breast Cancer | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Stage IIIC Gastric... and other conditions

United States
Five Prime Therapeutics, Inc.

Completed

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Gastric Cancer | Advanced Solid Tumors | Transitional Cell Carcinoma of the Bladder

Korea, Republic of, United States, Taiwan
Eli Lilly and Company

No longer available

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany, Netherlands, Austria, Greece, Korea, Republic of
Leap Therapeutics, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab (P102)

Esophageal Neoplasms | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma | Gastroesophageal Cancer

United States
Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Cancer of the Stomach | Gastroesophageal Junction

Brazil, Italy, United States, Argentina, Chile, Germany, Spain, Australia, Canada, Portugal, Mexico, Romania, Colombia, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Tempus AI

Recruiting

Tempus Priority Study: A Pan-tumor Observational Study

Lymphoma | Leukemia | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Lung Cancer | Prostate Cancer | Brain Cancer | Bladder Cancer | Cancer of Head and Neck | Peritoneal Cancer | Cancer of Liver | Cancer of Stomach | Cancer of Cervix | Cancer of Colon | Cancer of Rectum | Cancer of Gastrointestinal... and other conditions

United States
Seagen Inc.
Genmab

Completed

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Bladder Cancer | Cervix Cancer | Ovary Cancer | Esophagus Cancer | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Endometrium Cancer | Prostate Cancer (CRPC) | Lung Cancer(NSCLC)

United States, Belgium, United Kingdom, Denmark, Sweden
Xencor, Inc.
ICON plc

Completed

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Thymic Carcinoma | Thymoma | Non-small Cell Lung Carcinoma | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Cholangiocarcinoma | Breast Carcinoma | Fallopian Tube Carcinoma and other conditions

United States
Incyte Corporation

Completed

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castration Resistant Prostate Cancer | Gastric/ Gastroesophageal Junction | Squamous Carcinoma...

United States, Spain, France, United Kingdom, Italy, Belgium
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Carcinoma, Transitional Cell | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Biliary Tract Cancer | Adenocarcinoma of the Gastroesophageal Junction

Germany, United States, Spain, United Kingdom, France, Japan
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Incyte Biosciences International Sàrl

Completed

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions

United States
Incyte Corporation

Completed

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Stomach Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | NSCLC | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Gastroesophageal Junction Cancer | Urothelial... and other conditions

United States
Merrimack Pharmaceuticals

Unknown

A Study Evaluating MM-310 in Patients With Solid Tumors

Soft Tissue Sarcoma | Small Cell Lung Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Gastric Carcinoma | Solid Tumors | Pancreatic Ductal Adenocarcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Prostate Adenocarcinoma

United States
Xencor, Inc.
ICON plc

Active, not recruiting

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)

Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Advanced Solid Tumors | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Cervical Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma and other conditions

United States
Xencor, Inc.
ICON Clinical Research

Completed

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)

Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditions

United States
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada

Clinical Trials on Heterotopic Gastric Mucosa of the Proximal Esophagus in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations